红细胞氨甲喋呤多聚谷氨酸水平的测定：在类风湿关节炎中准备临床应用？
Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?
机构信息
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1530 3rd Avenue South, 178 SHEL, Birmingham, AL 35294-2182, USA.
出版信息
Curr Rheumatol Rep. 2010 Oct;12(5):342-7. doi: 10.1007/s11926-010-0120-3.
Abstract
Methotrexate (MTX) is one of the most commonly prescribed and most effective drugs for the treatment of rheumatoid arthritis (RA). Given the partial response of many patients and the side effect profile of the drug, there is considerable interest in identifying biomarkers to guide MTX therapy in RA. Upon entering cells, MTX is polyglutamated. Measuring MTX polyglutamate (MTX PG) levels in circulating red blood cells has been proposed as an objective measure to help optimize MTX therapy in RA. Data are conflicting with regard to the clinical utility of MTX PG measurements as a predictor of the efficacy or toxicity of low-dose MTX effects in RA. Should large, randomized clinical trials of this assay show consistent, reproducible, long-term correlations between MTX PG levels and efficacy or toxicity, this test could become a prominent tool for clinicians to optimize the use of MTX in treating RA.
摘要
甲氨蝶呤（MTX）是治疗类风湿关节炎（RA）最常用和最有效的药物之一。鉴于许多患者的部分缓解和药物的副作用特征，人们非常有兴趣确定生物标志物来指导 RA 中的 MTX 治疗。进入细胞后，MTX 会发生多聚谷氨酸化。测量循环红细胞中的 MTX 多聚谷氨酸（MTX PG）水平已被提议作为一种客观的方法来帮助优化 RA 中的 MTX 治疗。关于 MTX PG 测量作为预测低剂量 MTX 在 RA 中的疗效或毒性的指标的临床实用性，数据存在争议。如果这项检测的大型随机临床试验显示 MTX PG 水平与疗效或毒性之间存在一致、可重复、长期的相关性，那么该检测可能成为临床医生优化 MTX 治疗 RA 用途的重要工具。
相似文献
1
Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis?红细胞氨甲喋呤多聚谷氨酸水平的测定：在类风湿关节炎中准备临床应用？
Curr Rheumatol Rep. 2010 Oct;12(5):342-7. doi: 10.1007/s11926-010-0120-3.
2
Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis.类风湿关节炎中红细胞甲氨蝶呤多聚谷氨酸水平的决定因素
J Rheumatol. 2014 Nov;41(11):2167-78. doi: 10.3899/jrheum.131290. Epub 2014 Sep 15.
3
A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate.短链甲氨蝶呤聚谷氨酸作为接受甲氨蝶呤治疗的类风湿关节炎患者的结局参数。
Clin Exp Rheumatol. 2012 Mar-Apr;30(2):156-63. Epub 2012 Apr 13.
4
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells.红细胞中低剂量甲氨蝶呤及其多聚谷氨酸代谢物的群体药代动力学模型。
Clin Pharmacokinet. 2013 Jun;52(6):475-85. doi: 10.1007/s40262-013-0052-y.
5
Assessment of intracellular methotrexate and methotrexate-polyglutamate metabolite concentrations in erythrocytes by ultrafast matrix-assisted laser desorption/ionization triple quadrupole tandem mass spectrometry.采用超快基质辅助激光解吸/电离三重四极杆串联质谱法测定红细胞中甲氨蝶呤及其多聚谷氨酸代谢物浓度。
Rapid Commun Mass Spectrom. 2011 Oct 30;25(20):3063-70. doi: 10.1002/rcm.5202.
6
Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis.对类风湿关节炎患者开始使用甲氨蝶呤治疗时红细胞中甲氨蝶呤多聚谷氨酸盐与临床反应之间关系的评估。
Clin Pharmacokinet. 2014 Dec;53(12):1161-70. doi: 10.1007/s40262-014-0179-5.
7
Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis.循环红细胞和多形核细胞中的甲氨蝶呤多聚谷氨酸水平与类风湿关节炎的临床疗效相关。
Clin Exp Rheumatol. 1999 May-Jun;17(3):313-20.
8
Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate-polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis.预测类风湿关节炎患者在第 8 周时红细胞中甲氨蝶呤多聚谷氨酸浓度可预测第 24 周时甲氨蝶呤的治疗反应。
Mod Rheumatol. 2017 May;27(3):411-416. doi: 10.1080/14397595.2016.1208137. Epub 2016 Jul 20.
9
High Methotrexate Triglutamate Level Is an Independent Predictor of Adverse Effects in Asian Indian Rheumatoid Arthritis Patients-A Preliminary Study.高甲氨蝶呤三谷氨酸水平是亚洲印度类风湿关节炎患者不良反应的独立预测指标——一项初步研究
Ther Drug Monit. 2017 Apr;39(2):157-163. doi: 10.1097/FTD.0000000000000375.
10
Determination of erythrocyte methotrexate polyglutamates by liquid chromatography/tandem mass spectrometry after low-dose methotrexate therapy in Chinese patients with rheumatoid arthritis.采用液相色谱-串联质谱法测定低剂量甲氨蝶呤治疗类风湿关节炎中国患者的红细胞中甲氨蝶呤多聚谷氨酸。
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Oct 15;907:41-8. doi: 10.1016/j.jchromb.2012.08.032. Epub 2012 Sep 1.
引用本文的文献
1
Glutathione S-Transferase Gene Polymorphisms as Predictors of Methotrexate Efficacy in Juvenile Idiopathic Arthritis.谷胱甘肽S-转移酶基因多态性作为青少年特发性关节炎中氨甲蝶呤疗效的预测指标
Biomedicines. 2024 Jul 24;12(8):1642. doi: 10.3390/biomedicines12081642.
2
Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study.类风湿关节炎患者血清甲氨蝶呤多聚谷氨酸 3（MTX-PG3）水平与疾病活动的相关性：一项前瞻性队列研究。
F1000Res. 2022 Feb 15;11:187. doi: 10.12688/f1000research.108714.1. eCollection 2022.
3
Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.甲氨蝶呤治疗类风湿关节炎的药物微生物组学：肠道微生物组作为治疗反应的预测因子。
Front Immunol. 2021 Dec 16;12:789334. doi: 10.3389/fimmu.2021.789334. eCollection 2021.
4
Microbiota and Drug Response in Inflammatory Bowel Disease.炎症性肠病中的微生物群与药物反应
Pathogens. 2021 Feb 16;10(2):211. doi: 10.3390/pathogens10020211.
5
The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis.预处理肠道微生物组与新诊断类风湿关节炎患者对甲氨蝶呤无反应相关。
Arthritis Rheumatol. 2021 Jun;73(6):931-942. doi: 10.1002/art.41622. Epub 2021 May 2.
6
The evaluation of red blood cell folate and methotrexate levels during protocol M in childhood acute lymphoblastic leukemia.方案 M 治疗儿童急性淋巴细胞白血病期间红细胞叶酸和甲氨蝶呤水平的评估。
BMC Cancer. 2020 Sep 30;20(1):940. doi: 10.1186/s12885-020-07422-y.
7
Pharmacomicrobiomics in inflammatory arthritis: gut microbiome as modulator of therapeutic response.炎症性关节炎的药物微生物组学：肠道微生物组作为治疗反应的调节剂。
Nat Rev Rheumatol. 2020 May;16(5):282-292. doi: 10.1038/s41584-020-0395-3. Epub 2020 Mar 10.
8
Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model.甲氨蝶呤处置、抗叶酸活性和疗效在胶原诱导性关节炎小鼠模型中的作用。
Eur J Pharmacol. 2019 Jun 15;853:264-274. doi: 10.1016/j.ejphar.2019.03.052. Epub 2019 Apr 2.
9
The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies--a systematic review.测量炎症性关节病中红细胞甲氨蝶呤多聚谷氨酸浓度的作用及效用——一项系统评价
Eur J Clin Pharmacol. 2015 Apr;71(4):411-23. doi: 10.1007/s00228-015-1819-x. Epub 2015 Feb 18.
10
Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?类风湿关节炎中对甲氨蝶呤治疗反应的标志物：我们目前的状况如何？
Int J Rheumatol. 2012;2012:978396. doi: 10.1155/2012/978396. Epub 2012 Jul 9.
本文引用的文献
1
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.治疗类风湿关节炎的靶向治疗证据：系统文献检索结果。
Ann Rheum Dis. 2010 Apr;69(4):638-643. doi: 10.1136/ard.2009.123976.
2
Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations.青少年特发性关节炎患者细胞内甲氨蝶呤多聚谷氨酸盐的分析：给药途径对细胞内甲氨蝶呤多聚谷氨酸盐浓度变异性的影响
Arthritis Rheum. 2010 Jun;62(6):1803-12. doi: 10.1002/art.27434.
3
Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.依那西普联合甲氨蝶呤疗法与单一疗法治疗早期类风湿关节炎的两年临床和影像学结果：一项为期两年的双盲随机研究
Arthritis Rheum. 2010 Mar;62(3):674-82. doi: 10.1002/art.27268.
4
Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.在接受长期甲氨蝶呤治疗的类风湿关节炎患者中，甲氨蝶呤多聚谷氨酸盐浓度与疾病控制无关。
Arthritis Rheum. 2010 Feb;62(2):359-68. doi: 10.1002/art.27201.
5
Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.采用对症治疗、改善病情抗风湿药或生物制剂治疗极早期类风湿关节炎：一项成本效益分析。
Ann Intern Med. 2009 Nov 3;151(9):612-21. doi: 10.7326/0003-4819-151-9-200911030-00006.
6
Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation.甲氨蝶呤在类风湿性关节炎中分解代谢为7-羟基甲氨蝶呤会改变药物疗效和留存情况，补充叶酸可降低这种分解代谢。
Arthritis Rheum. 2009 Aug;60(8):2257-61. doi: 10.1002/art.24685.
7
Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment.接受长期甲氨蝶呤治疗的类风湿关节炎患者红细胞甲氨蝶呤多聚谷氨酸浓度的决定因素
Arthritis Rheum. 2009 Aug;60(8):2248-56. doi: 10.1002/art.24653.
8
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.甲氨蝶呤单药治疗类风湿关节炎患者的长期安全性：一项系统文献研究
Ann Rheum Dis. 2009 Jul;68(7):1100-4. doi: 10.1136/ard.2008.093690. Epub 2008 Dec 5.
9
Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis.类风湿关节炎患者口服甲氨蝶呤的药代动力学
Arthritis Rheum. 2008 Nov;58(11):3299-308. doi: 10.1002/art.24034.
10
Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy.接受甲氨蝶呤（MTX）治疗的类风湿性关节炎患者：稳态红细胞MTX浓度与血浆浓度及临床疗效相关。
J Rheumatol. 2008 Sep;35(9):1709-15. Epub 2008 Jul 15.
Zotero 插件